P2Y12 antagonists in acute coronary syndrome: In whom should they be started, and when?
Publication Date
2011
Journal Title
Curr Cardiol Rep
Abstract
Acute coronary syndromes reflect a spectrum of disease related, most commonly, to the sudden reduction in blood flow to a portion of myocardium. The underlying pathogenesis of the reduction in coronary flow is related to the sudden rupture of an atherosclerotic plaque, with subsequent thrombus formation leading to either vascular occlusion or microembolization. Clinicians combat this process with antithrombotic therapy, which typically includes both anticoagulant and antiplatelet therapy, and mechanical therapies, such as percutaneous coronary interventions, nearly always using stents. This review focuses on P2Y12 antagonists as one component of our armamentarium of antiplatelet therapies, specifically on data addressing in whom, when, which agent, and in what dose such agents should be administered. © Springer Science+Business Media, LLC 2011.
Volume Number
13
Issue Number
4
Pages
320 - 326
Document Type
Article
Status
Faculty
Facility
School of Medicine
Primary Department
Cardiology
Additional Departments
General Internal Medicine
PMID
DOI
10.1007/s11886-011-0184-3